As we wait, I just want to point out that we should not lose sight of the synergy that is a golden opportunity for Novartis.
Novartis and Mesoblast sure have an agreement looking at Remestemcel-L for treatment of (ARDS) and other indications but equally important is the role that Revascor (for CHF) can play in repairing COVID-19 induced heart damage.
Heart damage is seen in 50% of people hospitalized with COVID-19:
"A new study finds that about 50 percent of people hospitalized with severe COVID-19 will show evidence of heart damage — even months after recovering from the disease."
Click
here for link.
Also,
"Data from the U.K. Office for National Statistics, published on April 16, 2020, showed that 91 percent of those who died of COVID-19 in England and Wales in March 2020 had at least one underlying condition, with heart disease among the most common conditions (14 percent).A more recent review, published on October 6, 2020, in The American Journal of the Medical Sciences, found that the COVID-19 mortality rate for people with underlying cardiovascular disease was between 10.5 and nearly 14 percent. That number jumped to between 35 percent and almost 87 percent for people who had underlying coronary artery disease."
Click
here for link.
Further, here is the
damning evidence:
Anti-COVID-19 drugs themselves are causing heart damage:"....myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects".
Here is a peer -reviewed published article explaining that:
https://www.frontiersin.org/articles/10.3389/fphar.2021.699949/full
And let's not forget that myocarditis is increasing in people vaccinated with the mRNA COVID-19 vaccines.
This is just the tip of the iceberg, imo. What else is going to surface, as time passes, with the long term affects of vaccines?
https://jamanetwork.com/journals/jamacardiology/fullarticle/2781600Conclusion:
In addition to the synergy that we believe exists between Novartis' Entresto and Revascor for CHF, there is a huge, huge opportunity for treating COVID-19 induced heart damage and heart attacks in addition to the NON-COVID ones. This is in addition to the signed agreement looking at Remestemcel-L for treatment of (ARDS).
And as Dr. William Haseltine said, we need a multimodal approach to COVID-19. Vaccines alone are not going to get the job done. Vaccine efficacy, as we have been learning, is waning rather quickly anyway.
(20min delay)